Back to top
more

Pharming Group (PHAR)

(Delayed Data from NSDQ)

$9.73 USD

9.73
1,880

-0.28 (-2.75%)

Updated May 6, 2024 02:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

iTeos Therapeutics, Inc. (ITOS) Stock Jumps 5.4%: Will It Continue to Soar?

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Pharming Group N.V. Sponsored ADR (PHAR) Soars 14.7%: Is Further Upside Left in the Stock?

Pharming Group N.V. Sponsored ADR (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?

Pharming Group N.V. Sponsored ADR (PHAR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up

Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.

Why Earnings Season Could Be Great for Pharming Group (PHAR)

Pharming Group (PHAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Magenta (MGTA) Down on Pipeline Update for Leukemia Drug

Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.

Pharming Group N.V. Sponsored ADR (PHAR) is on the Move, Here's Why the Trend Could be Sustainable

Pharming Group N.V. Sponsored ADR (PHAR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Has Pharming Group (PHAR) Outpaced Other Medical Stocks This Year?

Here is how Pharming Group N.V. Sponsored ADR (PHAR) and POINT Biopharma Global Inc. (PNT) have performed compared to their sector so far this year.

Recent Price Trend in Pharming Group N.V. Sponsored ADR (PHAR) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Pharming Group N.V. Sponsored ADR (PHAR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Can Pharming Group N.V. Sponsored ADR (PHAR) Run Higher on Rising Earnings Estimates?

Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

Here is how Lantheus Holdings (LNTH) and Pharming Group N.V. Sponsored ADR (PHAR) have performed compared to their sector so far this year.